Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19078479 | 0.79 | ATM (0.41) | NR1H2ALDH1A1HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL34469349 | 0.73 | NR1H2 (0.39) | ADORA1NR1H2HSD17B10SMN1; SMN2 | |
| SCHEMBL21818930 | 0.73 | ATM (0.42) | ALDH1A1HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL21834515 | 0.73 | ATM (0.42) | ALDH1A1HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL26466455 | 0.73 | ALDH1A1 (0.35) | NR1H2ALDH1A1HSD17B10ATM | |
| SCHEMBL447448 | 0.73 | GHSR (0.40) | GHSR | |
| SCHEMBL26466448 | 0.71 | ALDH1A1 (0.34) | ALDH1A1GHSRATMSMN1; SMN2 | |
| SCHEMBL12162581 | 0.71 | MTNR1B (0.48) | NR1H2GHSR | |
| SCHEMBL18759956 | 0.70 | CYP3A4 (0.47) | SMN1; SMN2 | |
| SCHEMBL6536207 | 0.70 | ALDH1A1 (0.40) | ALDH1A1HSD17B10ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | ADORA1 1560/4885NR1H2 246/4885ALDH1A1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.